Literature DB >> 21419848

Loss of the tuberous sclerosis complex protein tuberin causes Purkinje cell degeneration.

R Michelle Reith1, Sharon Way, James McKenna, Katherine Haines, Michael J Gambello.   

Abstract

Tuberous sclerosis complex (TSC) is a neurogenetic disorder that often causes brain abnormalities leading to epilepsy, developmental delay, and autism. TSC is caused by inactivating mutations in either of the genes encoding the proteins hamartin (TSC1) and tuberin (TSC2). These proteins form a heterodimer that inhibits the mammalian target of rapamycin complex 1 (mTORC1) pathway, controlling translation and cell growth. Loss of either protein results in dysregulated mTORC1 activation, an important aspect of TSC pathogenesis. About thirty percent of TSC patients have cerebellar pathology that is poorly understood. To investigate the effects of TSC on the cerebellum, we created a mouse model in which the Tsc2 gene was selectively deleted from Purkinje cells starting at postnatal day 6 (P6). The loss of Tsc2 caused a progressive increase in Purkinje cell size and subsequent death from apoptosis. Purkinje cell loss was predominantly cell type specific and associated with motor deficits. Immunohistochemical analysis showed that both endoplasmic reticulum (ER) and oxidative stress were increased in Tsc2-null Purkinje cells. The cell death and ER stress phenotypes were rescued by treatment with the mTORC1 inhibitor rapamycin. To assess whether the murine Purkinje cell loss has a correlate to the human TSC, we analyzed postmortem cerebellum samples from TSC patients and detected Purkinje cell loss in half of the samples. Our results establish a critical role for the TSC complex in Purkinje cell survival by regulating ER and oxidative stress and reveal a novel aspect of TSC neuropathology.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21419848      PMCID: PMC3096682          DOI: 10.1016/j.nbd.2011.02.014

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  57 in total

1.  Autism and the cerebellum: evidence from tuberous sclerosis.

Authors:  A M Weber; J C Egelhoff; J M McKellop; D N Franz
Journal:  J Autism Dev Disord       Date:  2000-12

2.  Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling.

Authors:  Ken Inoki; Yong Li; Tian Xu; Kun-Liang Guan
Journal:  Genes Dev       Date:  2003-07-17       Impact factor: 11.361

3.  Autism in tuberous sclerosis complex is related to both cortical and subcortical dysfunction.

Authors:  E Asano; D C Chugani; O Muzik; M Behen; J Janisse; R Rothermel; T J Mangner; P K Chakraborty; H T Chugani
Journal:  Neurology       Date:  2001-10-09       Impact factor: 9.910

4.  Neurofibromas in NF1: Schwann cell origin and role of tumor environment.

Authors:  Yuan Zhu; Pritam Ghosh; Patrick Charnay; Dennis K Burns; Luis F Parada
Journal:  Science       Date:  2002-05-03       Impact factor: 47.728

5.  The TSC1 and TSC2 tumor suppressors are required for proper ER stress response and protect cells from ER stress-induced apoptosis.

Authors:  Y J Kang; M-K Lu; K-L Guan
Journal:  Cell Death Differ       Date:  2010-07-09       Impact factor: 15.828

6.  Patterns of cerebellar atrophy in patients with chronic epilepsy: a quantitative neuropathological study.

Authors:  R Crooks; T Mitchell; M Thom
Journal:  Epilepsy Res       Date:  2000-08       Impact factor: 3.045

7.  Why do Purkinje cells die so easily after global brain ischemia? Aldolase C, EAAT4, and the cerebellar contribution to posthypoxic myoclonus.

Authors:  John P Welsh; Genevieve Yuen; Dimitris G Placantonakis; Toan Q Vu; Florent Haiss; Elizabeth O'Hearn; Mark E Molliver; Sue A Aicher
Journal:  Adv Neurol       Date:  2002

8.  Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma.

Authors:  Nisreen El-Hashemite; Hongbing Zhang; Elizabeth P Henske; David J Kwiatkowski
Journal:  Lancet       Date:  2003-04-19       Impact factor: 79.321

9.  Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins.

Authors:  Yong Zhang; Xinsheng Gao; Leslie J Saucedo; Binggen Ru; Bruce A Edgar; Duojia Pan
Journal:  Nat Cell Biol       Date:  2003-06       Impact factor: 28.824

Review 10.  Purkinje cell vulnerability and autism: a possible etiological connection.

Authors:  Janet Kinnear Kern
Journal:  Brain Dev       Date:  2003-09       Impact factor: 1.961

View more
  35 in total

Review 1.  mTOR signaling in epilepsy: insights from malformations of cortical development.

Authors:  Peter B Crino
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

2.  Impaired social interactions and motor learning skills in tuberous sclerosis complex model mice expressing a dominant/negative form of tuberin.

Authors:  Itzamarie Chévere-Torres; Jordan M Maki; Emanuela Santini; Eric Klann
Journal:  Neurobiol Dis       Date:  2011-07-30       Impact factor: 5.996

Review 3.  Consensus paper: pathological role of the cerebellum in autism.

Authors:  S Hossein Fatemi; Kimberly A Aldinger; Paul Ashwood; Margaret L Bauman; Charles D Blaha; Gene J Blatt; Abha Chauhan; Ved Chauhan; Stephen R Dager; Price E Dickson; Annette M Estes; Dan Goldowitz; Detlef H Heck; Thomas L Kemper; Bryan H King; Loren A Martin; Kathleen J Millen; Guy Mittleman; Matthew W Mosconi; Antonio M Persico; John A Sweeney; Sara J Webb; John P Welsh
Journal:  Cerebellum       Date:  2012-09       Impact factor: 3.847

4.  Imbalanced mechanistic target of rapamycin C1 and C2 activity in the cerebellum of Angelman syndrome mice impairs motor function.

Authors:  Jiandong Sun; Yan Liu; Stephanie Moreno; Michel Baudry; Xiaoning Bi
Journal:  J Neurosci       Date:  2015-03-18       Impact factor: 6.167

5.  Decreased rates of cerebral protein synthesis measured in vivo in a mouse model of Tuberous Sclerosis Complex: unexpected consequences of reduced tuberin.

Authors:  Rachel Michelle Saré; Tianjian Huang; Tom Burlin; Inna Loutaev; Carolyn Beebe Smith
Journal:  J Neurochem       Date:  2018-04-02       Impact factor: 5.372

Review 6.  Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders.

Authors:  Kenneth Maiese
Journal:  Br J Clin Pharmacol       Date:  2015-12-26       Impact factor: 4.335

Review 7.  Advancing the discovery of medications for autism spectrum disorder using new technologies to reveal social brain circuitry in rodents.

Authors:  Martien J Kas; Meera E Modi; Michael D Saxe; Daniel G Smith
Journal:  Psychopharmacology (Berl)       Date:  2014-02-13       Impact factor: 4.530

Review 8.  Pre-clinical models of neurodevelopmental disorders: focus on the cerebellum.

Authors:  Alexey V Shevelkin; Chinezimuzo Ihenatu; Mikhail V Pletnikov
Journal:  Rev Neurosci       Date:  2014       Impact factor: 4.353

9.  Tuberous sclerosis protein 2 (TSC2) modulates CCN4 cytoprotection during apoptotic amyloid toxicity in microglia.

Authors:  Yan Chen Shang; Zhao Zhong Chong; Shaohui Wang; Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2013-02       Impact factor: 1.990

10.  A magnetic resonance imaging study of cerebellar volume in tuberous sclerosis complex.

Authors:  Neil I Weisenfeld; Jurriaan M Peters; Peter T Tsai; Sanjay P Prabhu; Kira A Dies; Mustafa Sahin; Simon K Warfield
Journal:  Pediatr Neurol       Date:  2013-02       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.